Revolution Medicines Drug Patent Portfolio

Revolution Medicines owns 1 orange book drug protected by 2 US patents Given below is the list of Revolution Medicines's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12280113 Ras Inhibitors 24 Jan, 2042
Active
US12403196 Ras Inhibitors 15 Sep, 2041
Active


Revolution Medicines's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Revolution Medicines:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Revolution Medicines, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Revolution Medicines, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Revolution Medicines, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) Revolution Medicines, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC Revolution Medicines, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma Revolution Medicines, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) Revolution Medicines, Inc. NA RECRUITING
(Jul 1, 2026)
PHASE3
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Revolution Medicines, Inc. NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2


Revolution Medicines Drug List

Given below is the complete list of Revolution Medicines's drugs and the patents protecting them.


1. Rasonque

Rasonque is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12280113 Ras Inhibitors 24 Jan, 2042
(15 years from now)
Active
US12403196 Ras Inhibitors 15 Sep, 2041
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rasonque's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List